生物标志物在老年人心力衰竭鉴别诊断中的效用：来自护理院心力衰竭（HFinCH）诊断准确性研究的数据集

数据集获取（Figshare）

• 源站标题：Utility of Biomarkers in the Differential Diagnosis of Heart Failure in Older People: Findings from the Heart Failure in Care Homes (HFinCH) Diagnostic Accuracy Study
• DOI：10.1371/journal.pone.0053560
• 发布日期：2013-01-11
• 文件数：2 个
• 文件总体积：48.27 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Utility_of_Biomarkers_in_the_Differential_Diagnosis_of_Heart_Failure_in_Older_People_Findings_from_the_Heart_Failure_in_Care_Homes_HFinCH_Diagnostic_Accuracy_Study__/114615

命令行下载

curl -L -o "Table_S1.docx" "https://ndownloader.figshare.com/files/277098"
curl -L -o "Table_S2.docx" "https://ndownloader.figshare.com/files/277141"

文件清单

• Table_S1.docx（17.30 KB）
• Table_S2.docx（30.97 KB）

文件总体积 48.27 KB（源站 API 实测）。

数据说明

Background
The performance of biomarkers for heart failure (HF) in older residents in long-term care is poorly understood and has not differentiated between left ventricular systolic dysfunction (LVSD) and HF with preserved ejection fraction (HFpEF).
Methods
This is the first diagnostic accuracy study in this population to assess the differential diagnostic performance and acceptability of a range of biomarkers against a clinical diagnosis using portable echocardiography. A total of 405 residents, aged 65–100 years (mean 84.2), in 33 UK long-term care facilities were enrolled between April 2009 and June 2010.
Results
For undifferentiated HF, BNP or NT-proBNP were adequate rule-out tests but would miss one in three cases (BNP: sensitivity 67%, NPV 86%, cut-off 115 pg/ml; NT-proBNP: sensitivity 62%, NPV 87%, cut-off 760 pg/ml). Using higher test cut-offs, both biomarkers were more adequate tests of LVSD, but would still miss one in four cases (BNP: sensitivity 76%, NPV 97%, cut-off 145 pg/ml; NT-proBNP: sensitivity 73%, NPV 97%, cut-off 1000 pg/ml). At these thresholds one third of subjects would test positive and require an echocardiogram. Applying a stricter ‘rule out’ threshold (sensitivity 90%), only one in 10 cases would be missed, but two thirds of subjects would require further investigation. Biomarkers were less useful for HFpEF (BNP: sensitivity 63%, specificity 61%, cut-off 110 pg/ml; NT-proBNP: sensitivity 68%, specificity 56%, cut-off 477 pg/ml). Novel biomarkers (Copeptin, MR-proADM, and MR-proANP) and common signs and symptoms had little diagnostic utility.
Conclusions
No test, individually or in combination, adequately balanced case finding and rule-out for heart failure in this population; currently, in-situ echocardiography provides the only adequate diagnostic assessment.
Trial Registration
Controlled-Trials.com ISRCTN19781227

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0053560（source: https://plos.figshare.com/articles/dataset/Utility_of_Biomarkers_in_the_Differential_Diagnosis_of_Heart_Failure_in_Older_People_Findings_from_the_Heart_Failure_in_Care_Homes_HFinCH_Diagnostic_Accuracy_Study__/114615）。